Investigational drug · Phase 2
INV-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "INV-102"
First trial start
2024
Sep 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INV-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-center Involved Diabetic Macular Edema
- Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
- Diabetic Retinopathy
- Center-involved Diabetic Macular Edema
- Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "INV-102" as an intervention, largest first.
- Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye DiseasePivotal-lookingCompleted
Invirsa, Inc.Industry
NCT06370039 · 109 participants · Start Mar 27, 2024 · Primary completion Jul 3, 2024
Drug: INV-102; Vehicle · For: Dry Eye Disease
Sites: Rush, New York
Invirsa, Inc.Industry
NCT05636228 · 93 participants · Start Jun 9, 2023 · Primary completion Aug 22, 2024
Drug: INV-102; Vehicle · For: Acute Infectious Keratoconjunctivitis
Sites: Glendale, California; Pasadena, California; Largo, Florida · 12 sites in all
Invirsa, Inc.Industry
NCT05586152 · 84 participants · Start Aug 30, 2022 · Primary completion May 2, 2023
Drug: INV-102; Vehicle · For: Dry Eye Disease
Sites: Rush, New York
Invirsa, Inc.Industry
NCT06599684 · 19 participants · Start Sep 7, 2024 · Primary completion Sep 30, 2025
Drug: INV-102 · For: Non-center Involved Diabetic Macular Edema; Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy; Diabetic Retinopathy and 2 more
Sites: Dallas, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Treatment of Sulfur Mustard Corneal Injury by Augmenting the DNA Damage Response (DDR): A Novel Approach.
Shalwitz R, Day T, Ruehlmann AK, et al. · J Pharmacol Exp Ther 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.